Silver Falcon Plc, (LSE: SILF), which has agreed to acquire the biotechnology company Hemogenyx Pharmaceuticals Limited (“Hemogenyx”), announces that following a General Meeting of the Company today all resolutions were duly approved by shareholders, including in relation to the waiver of Rule 9 of the Takeover Code and the Placing and Subscription.

Accordingly, the Acquisition and the related Placing and Subscription will complete tomorrow, 5 October 2017, subject only to the readmission of the enlarged share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange (“Admission”), which is expected to commence at 8.00 a.m. on 5 October 2017.

On Admission, the Company’s total issued share capital will consist of 356,042,854 Ordinary Shares of £0.01 each.  The Company holds no Ordinary Shares in treasury.  The above figure (356,042,854) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Hemogenyx Pharmaceuticals plc under the FCA’s Disclosure Guidance and Transparency Rules.

The Company will trade under the new company name of Hemogenyx Pharmaceuticals Plc and the Company’s new London Stock Exchange TIDM ticker symbol will be HEMO and its ISIN will remain as GB00BYX3WZ24.

In addition, the Company’s new website address will be www.hemogenyx.com

 

Hemogenyx Pharmaceuticals Limited	www.hemogenyx.com
Peter Redmond, Director	Via Walbrook PR
Optiva Securities Ltd	Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP	Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited	Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR	Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893
Flowcomms IR	Mob: +44 (0)7891 627 441 or sasha@flowcomms.com
Sasha Sethi